檢索結果 - Anil Londhe
- Showing 1 - 6 results of 6
-
1
P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA 由 Ajai Chari, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric Ammann, Christoph Heuck, Colleen Kane, Anil Londhe, Steve Peterson, Donna Reece
發表在 HemaSphere (2023-08-01)獲取全文
Article -
2
P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS 由 Albert Oriol, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Christoph Heuck, Thomas Renaud, Colleen Kane, Trilok Parekh, Steve Peterson
發表在 HemaSphere (2023-08-01)獲取全文
Article -
3
PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA 由 Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Steve Peterson, Luciano Costa
發表在 HemaSphere (2023-08-01)獲取全文
Article -
4
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma 由 Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Saad Z Usmani
發表在 Journal of Comparative Effectiveness Research (2023-04-01)Article -
5
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-do... 由 María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo
發表在 Haematologica (2014-06-01)獲取全文
Article -
6
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment... 由 Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath
發表在 eJHaem (2022-02-01)獲取全文
Article
